Literature DB >> 16637424

[Cerebellar hematomas. Description of a cohort and prognosis based on therapeutic attitude].

B Virgós-Señor1, A C Nebra-Puertas, J Villagrasa-Compaired, J Van Popta.   

Abstract

OBJECTIVES: Spontaneous cerebellar hematomas (CH) represent 5%-10% of intracranial hemorrhaging. We describe the existing cardiovascular risk factors, clinical presentation of CH and its relationship with mortality and the association between the treatment type (conservative medical or neurosurgical treatment) and the subsequent course of the patients. DESIGN AND SCOPE: Observational study of patients diagnosed of CH admitted over three years in an Intensive Care Unit of a level III Hospital. PATIENTS: Fifty-six consecutive patients diagnosed of CH. VARIABLES OF PRINCIPAL INTEREST: We studied the cardiovascular risk factors, presentation form (with Glasgow Coma Scale- GCS), hematoma size and site, and morbidity-mortality of the patients (with the Glasgow Outcome Scale--GOS).
RESULTS: Fisher's exact test, Chi squared, calculation of Spearman's coefficient between certain variables and logistic regression analysis were used. Hematoma size, GCS on admission and presence of hydrocephaly obtained statistical significance. Conservative medical treatment has greater mortality.
CONCLUSIONS: Patients with GCS < or = 8 and hematoma size > or = 3 cm benefit from surgical treatment. Initial GCS and vermian site are mortality predictor factors. There is no more morbidity due to surgical treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16637424     DOI: 10.1016/s0210-5691(06)74454-0

Source DB:  PubMed          Journal:  Med Intensiva        ISSN: 0210-5691            Impact factor:   2.491


  1 in total

1.  Platelet count and early outcome in patients with spontaneous cerebellar hemorrhage: a retrospective study.

Authors:  Ching-Yueh Lin; Chih-Ya Chang; Chia-Hung Sun; Tsung-Ying Li; Liang-Cheng Chen; Shin-Tsu Chang; Yung-Tsan Wu
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.